Arthritis

Global Ankylosing Spondylitis Market (2021 to 2028) - Share, Size, Trends and Industry Analysis Report - ResearchAndMarkets.com

Friday, May 14, 2021 - 3:17pm

b'The "Ankylosing Spondylitis Market Share, Size, Trends, Industry Analysis Report, By Drug; By Treatment Type; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global ankylosing spondylitis market size is expected to reach USD 8.45 billion by 2028 according to a new study.

Key Points: 
  • b'The "Ankylosing Spondylitis Market Share, Size, Trends, Industry Analysis Report, By Drug; By Treatment Type; By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global ankylosing spondylitis market size is expected to reach USD 8.45 billion by 2028 according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.\nAnkylosing Spondylitis (AS), also known as Bechterew disease is the rare type of arthritis causing stiffness and intense pain in the individual\'s spine, starting from lower back sacral bones.
  • Ankylosing spondylitis is started from an individual\'s sacroiliac joints, where the spinal cord connects with the pelvic girdle.
  • According to the recent population estimates the prevalence rate of ankylosing spondylitis in the U.S. is around 0.2-0.5 percent and based on market data from multiple countries the global incidence rate stood at 0.4-14 per 100,000 individuals.\n'

Global Gout Markets, Epidemiology and Patient Flow Report 2020-2035: Focus on US, Germany, France, Italy, Spain, UK, Japan, G7 Countries - ResearchAndMarkets.com

Friday, May 14, 2021 - 10:05am

b'The "Global Gout Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Gout Epidemiology and Patient Flow Analysis - 2021, provides Gout epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Gout Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Gout Epidemiology and Patient Flow Analysis - 2021, provides Gout epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Gout patients, history of the disease at the population level (Gout prevalence, Gout incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Gout patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Gout market sizing, assessing market potential, and developing drug forecast models\nIdentify Gout patients segments through age groups, gender, and disease sub-types\n'

Global Rheumatoid Arthritis Markets, Epidemiology and Patient Flow Report 2020-2035 - ResearchAndMarkets.com

Friday, May 14, 2021 - 10:03am

b'The "Global Rheumatoid Arthritis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Rheumatoid Arthritis Epidemiology and Patient Flow Analysis - 2021, provides Rheumatoid Arthritis epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Rheumatoid Arthritis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Rheumatoid Arthritis Epidemiology and Patient Flow Analysis - 2021, provides Rheumatoid Arthritis epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Rheumatoid Arthritis patients, history of the disease at the population level (Rheumatoid Arthritis prevalence, Rheumatoid Arthritis incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Rheumatoid Arthritis patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Rheumatoid Arthritis market sizing, assessing market potential, and developing drug forecast models\nIdentify Rheumatoid Arthritis patients segments through age groups, gender, and disease sub-types\nEvaluate Rheumatoid Arthritis market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005184/en/\n'

Anika to Host its 2021 Virtual Investor Day on June 3, 2021

Thursday, May 13, 2021 - 4:00pm

The event will include presentations followed by a Q&A panel session with senior leadership.

Key Points: 
  • The event will include presentations followed by a Q&A panel session with senior leadership.
  • We partner with physicians to understand what they need most to treat their patients and we develop minimally invasive products that restore active living for people around the world.
  • We are committed to leading in high opportunity spaces within orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair and bone preserving joint technologies.
  • For more information, please visit www.anika.com .\n"

Worldwide Psoriatic Arthritis Industry to 2035 - Identify Market Opportunities - ResearchAndMarkets.com

Thursday, May 13, 2021 - 11:37am

b'The "Global Psoriatic Arthritis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis report provides Psoriatic Arthritis epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Psoriatic Arthritis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis report provides Psoriatic Arthritis epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Psoriatic Arthritis patients, history of the disease at the population level (Psoriatic Arthritis prevalence, Psoriatic Arthritis incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Psoriatic Arthritis patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Psoriatic Arthritis market sizing, assessing market potential, and developing drug forecast models\nIdentify Psoriatic Arthritis patients segments through age groups, gender, and disease sub-types\nEvaluate Psoriatic Arthritis market opportunities, identify target patient population\n'

2021 Insights on the Ankylosing Spondylitis Global Market - Identify Target Patient Population - ResearchAndMarkets.com

Thursday, May 13, 2021 - 11:36am

b'The "Global Ankylosing Spondylitis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis report provides Ankylosing Spondylitis epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Ankylosing Spondylitis Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThis report provides Ankylosing Spondylitis epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Ankylosing Spondylitis patients, history of the disease at the population level (Ankylosing Spondylitis prevalence, Ankylosing Spondylitis incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Ankylosing Spondylitis patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Ankylosing Spondylitis market sizing, assessing market potential, and developing drug forecast models\nIdentify Ankylosing Spondylitis patients segments through age groups, gender, and disease sub-types\nEvaluate Ankylosing Spondylitis market opportunities, identify target patient population\n'

Ankylosing Spondylitis Pipeline Market Report 2021: Comprehensive Insights of Approx 40+ Companies and Pipeline Drugs - ResearchAndMarkets.com

Thursday, May 13, 2021 - 9:58am

b'The "Ankylosing Spondylitis- Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis "Ankylosing Spondylitis- Pipeline Insight, 2021," report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Ankylosing Spondylitis pipeline landscape.\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products.

Key Points: 
  • b'The "Ankylosing Spondylitis- Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis "Ankylosing Spondylitis- Pipeline Insight, 2021," report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Ankylosing Spondylitis pipeline landscape.\nIt covers the pipeline drug profiles, including clinical and nonclinical stage products.
  • It further highlights the inactive pipeline products in this space.\nThe companies and academics are working to assess challenges and seek opportunities that could influence Ankylosing Spondylitis R&D.
  • It is in Phase III of clinical trial.\nThis segment of the report provides insights about the different Ankylosing Spondylitis drugs segregated based on following parameters that define the scope of the report, such as:\nThere are approx.
  • Preregistration include, Pfizer.\nAnkylosing Spondylitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

New ACR White Paper Highlights Health Care Challenges Affecting the Rheumatic Disease Community

Wednesday, May 12, 2021 - 5:28pm

\xe2\x80\x9cWith this white paper, we aim to create an accessible, introductory resource for those interested in learning more about rheumatic disease, current treatment options, and the health care and lifestyle challenges patients with rheumatic disease face.\xe2\x80\x9d\nThe white paper is written and designed to appeal to multiple audiences and consists of four key sections:\nThis section provides an introduction to what a rheumatic disease is, describes the role of a rheumatologist, and discusses the importance of early and appropriate treatment.

Key Points: 
  • \xe2\x80\x9cWith this white paper, we aim to create an accessible, introductory resource for those interested in learning more about rheumatic disease, current treatment options, and the health care and lifestyle challenges patients with rheumatic disease face.\xe2\x80\x9d\nThe white paper is written and designed to appeal to multiple audiences and consists of four key sections:\nThis section provides an introduction to what a rheumatic disease is, describes the role of a rheumatologist, and discusses the importance of early and appropriate treatment.
  • Patients and their family members \xe2\x80\x93 particularly those who may have been recently diagnosed with a rheumatic disease \xe2\x80\x93 may find this section helpful in understanding what to expect after a diagnosis.
  • This white paper discusses what some of these diseases are and how they affect different parts of the body.\nRheumatic diseases in America are extremely common.
  • Rheumatology professionals are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases.\n'

ZetrOZ CEO Discusses Sustained Acoustic Medicine With Medical Devices Group

Wednesday, May 12, 2021 - 3:00pm

"Waiting over a decade for new breakthroughs is simply unacceptable; there\'s more we can do within the medical community to push these technologies to the forefront and get them into the hands of people that can truly benefit from them.

Key Points: 
  • "Waiting over a decade for new breakthroughs is simply unacceptable; there\'s more we can do within the medical community to push these technologies to the forefront and get them into the hands of people that can truly benefit from them.
  • Providers are often unwilling to cover the costs of new innovations.
  • Many expect to see extensive doctor utilization before they will start paying for a new treatment.
  • ZetrOZ Systems produced UltrOZ, samSport and samPro 2.0 to provide safe and effective treatment options for prevalent conditions such as arthritis.

Worldwide Granulomatosis with Polyangiitis Industry to 2030 - ResearchAndMarkets.com

Wednesday, May 12, 2021 - 11:47am

b'The "Granulomatosis with Polyangiitis - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nThis report delivers an in-depth understanding of the historical and forecasted epidemiology of GPA in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.\nThe disease epidemiology covered in the report provides historical and forecasted GPA epidemiology segmented as the Incident cases of granulomatosis with polyangiitis, Gender-specific cases of granulomatosis with polyangiitis and Age-specific cases of granulomatosis with polyangiitis.

Key Points: 
  • b'The "Granulomatosis with Polyangiitis - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com\'s offering.\nThis report delivers an in-depth understanding of the historical and forecasted epidemiology of GPA in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.\nThe disease epidemiology covered in the report provides historical and forecasted GPA epidemiology segmented as the Incident cases of granulomatosis with polyangiitis, Gender-specific cases of granulomatosis with polyangiitis and Age-specific cases of granulomatosis with polyangiitis.
  • Among the EU5 countries, Germany had the largest incident population of GPA with 2,722 cases, followed by the UK in 2020.
  • The opinion helps understand the total patient population and current treatment pattern.
  • Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources\n'